(Total Views: 550)
Posted On: 02/12/2021 11:40:48 AM
Post# of 148870
I'm really surprised we didn't hear anything this week. I expected at a minimum, to find out if/when the unblinding occurred.
This silence is very unusual. The question is, why are they being silent?
Just going to brainstorm all the potential reasons I can think of. Feel free to add:
1) Amarex is slow, or there have been delays. Unblinding hasn't occurred yet.
2) Unblinding did occur, and the data was sent to the FDA. FDA asked us to remain silent while they analyze. Who knows when they will finish...
3) Unblinding has occured, and we missed the PE. So they are reviewing all of the secondary data to find reasons for EUA.
4) Unblinding has occured, data sent to FDA. The data is very strong, so company is working on all of the logistics of distributing the doses, increasing production, etc while the FDA is reviewing the data. Perhaps we are also assembling our EUA submission. They dont want to do anything to jeopardize things, so they are choosing to remain quiet.
What else ya got?
This silence is very unusual. The question is, why are they being silent?
Just going to brainstorm all the potential reasons I can think of. Feel free to add:
1) Amarex is slow, or there have been delays. Unblinding hasn't occurred yet.
2) Unblinding did occur, and the data was sent to the FDA. FDA asked us to remain silent while they analyze. Who knows when they will finish...
3) Unblinding has occured, and we missed the PE. So they are reviewing all of the secondary data to find reasons for EUA.
4) Unblinding has occured, data sent to FDA. The data is very strong, so company is working on all of the logistics of distributing the doses, increasing production, etc while the FDA is reviewing the data. Perhaps we are also assembling our EUA submission. They dont want to do anything to jeopardize things, so they are choosing to remain quiet.
What else ya got?
(8)
(0)Scroll down for more posts ▼
